Firefly Neuroscience, Inc. (AIFF) - Q3 2025 10-Q Summary
Business Context and Reporting Period
This Quarterly Report on Form 10-Q covers the period ended September 30, 2025. Firefly Neuroscience, Inc. is an AI technology company developing neuroscientific solutions, including the FDA-cleared BNA™ platform and the Evox System. The company completed a reverse merger with WaveDancer in August 2024 and acquired Evoke Neuroscience, Inc. on April 30, 2025, to expand its hardware and software capabilities for measuring brain electrical activity.
Key Financial Metrics
| Metric | Q3 2025 (3 Months) | YTD 2025 (9 Months) | YTD 2024 (9 Months) |
|---|---|---|---|
| Revenue | $388,000 | $730,000 | $55,000 |
| Gross Profit | $146,000 | $463,000 | $55,000 |
| Net Loss | $(2,639,000) | $(17,402,000) | $(6,675,000) |
| Operating Cash Flow | N/A | $(6,389,000) | $(4,937,000) |
| Cash and Equivalents (End of Period) | $4,325,000 | $4,325,000 | $1,230,000 |
| Total Assets | $12,407,000 | $12,407,000 | $4,601,000 |
| Accumulated Deficit | $(108,896,000) | $(108,896,000) | $(87,084,000) |
Note: All figures in thousands except per share data.
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 1,076% in Q3 and 1,227% YTD compared to 2024, primarily driven by the inclusion of Evoke Neuroscience operations following the April 2025 acquisition.
- Expense Reduction: Operating expenses decreased significantly in Q3 (down 35% from Q3 2024) due to reduced legal fees and consultant costs associated with the 2024 merger and rebranding. However, YTD G&A expenses increased 19% due to higher D&O insurance costs and fees from cancelling an equity line of credit.
- Non-Cash Charges: The YTD 2025 net loss was heavily impacted by a $9,369,000 loss on the change in derivative fair value and a $1,353,000 loss on the settlement of a convertible promissory note upon conversion to equity. Additionally, a $152,000 impairment charge was recorded for intangible assets (BNA software) due to a strategic shift.
- Balance Sheet Expansion: Total assets more than doubled from $4.6M to $12.4M, driven by the acquisition of Evoke (recording $5.2M in goodwill) and increased cash reserves from financing activities.
Outlook, Risks, and Management Commentary
- Going Concern: The filing explicitly states there is substantial doubt about the company's ability to continue as a going concern due to recurring losses, an accumulated deficit of $108.9M, and negative operating cash flows. Continued operations depend on raising additional capital.
- Capital Raising: The company raised significant capital in the first nine months of 2025 through private placements (March and June 2025 Units Offerings) and warrant exercises, generating over $11M in financing cash flows.
- Strategic Focus: Management plans to integrate Evoke and BNA products to drive recurring revenue. They are expanding sales efforts to healthcare professionals and pharmaceutical companies.
- Internal Controls: Management identified material weaknesses in internal controls over financial reporting, specifically regarding Information Technology General Controls (ITGCs) and lack of segregation of duties. Remediation is projected for Q1 2026.
- Risks: Key risks include the inability to secure future funding, regulatory challenges for AI/ML medical devices, and geopolitical instability affecting operations in Israel.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $4.3M cash balance against the $6.4M YTD operating cash burn rate to assess immediate liquidity needs.
- Derivative Accounting: Review the $9.4M non-cash loss on derivative fair value to understand its impact on reported net loss versus operational performance.
- Acquisition Integration: Monitor the realization of synergies from the Evoke acquisition and the performance of the $5.2M goodwill recorded.
- Internal Control Remediation: Track progress on fixing ITGC and segregation of duties weaknesses to ensure future financial reporting reliability.
- Dilution: Assess the impact of recent equity issuances and outstanding warrants (1.7M warrants) on future share count and per-share value.